John Friend
Net worth: 150 $ as of 31/05/2026
Net worth: 150 $ as of 31/05/2026
John E.
Friend is Chief Executive Officer & Director at Kazia Therapeutics Ltd. since 2024.
Formerly, Senior Vice President-Medical & Scientific Affairs at Helsinn Therapeutics (U.S.), Inc. from 2010 to 2017.
Chief Medical Officer & Vice President at Cellectar Biosciences, Inc. from 2017 to 2018 and again from 2020 to 2021.
Chief Medical Officer at Druggability Technologies Holdings Ltd. (New Jersey).
Education includes undergraduate studies at Southern Methodist University and a doctorate from Robert Wood Johnson Medical School.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 18/03/2026 | 15,000,000 ( 0.26% ) | 150 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| KAZIA THERAPEUTICS LIMITED | Chief Executive Officer | 01/05/2023 |
| Companies | Position | End |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 02/11/2021 |
| CELLECTAR BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 27/11/2018 |
Helsinn Therapeutics (U.S.), Inc.
Helsinn Therapeutics (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and supplies pharmaceutical products for treatment of cancer | Chief Tech/Sci/R&D Officer | 01/04/2017 |
Druggability Technologies Holdings Ltd. (New Jersey) | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Kazia Therapeutics Ltd.
Kazia Therapeutics Ltd. BiotechnologyHealth Technology Engages in the business of pharmaceutical research and development | Health Technology |
Southern Methodist University
Southern Methodist University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Robert Wood Johnson Medical School
Robert Wood Johnson Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Helsinn Therapeutics (U.S.), Inc.
Helsinn Therapeutics (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and supplies pharmaceutical products for treatment of cancer | Health Technology |
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer | Health Technology |
Druggability Technologies Holdings Ltd. (New Jersey) |
Select your edition
All financial news and data tailored to specific country editions